Magnolia Medical Technologies

Magnolia Medical Technologies is a medical device company that focuses on developing and manufacturing advanced blood and bodily fluid collection devices. Their flagship product, the Steripath® Initial Specimen Diversion Device® (ISDD®), uses a patented technique to significantly reduce blood culture contamination, which is a common cause of false-positive results in sepsis testing. The Steripath device is FDA 510(k)-cleared and has been clinically proven to lower contamination rates by 83% to 88%, enhancing diagnostic accuracy and supporting better clinical decisions. In addition to their collection devices, Magnolia Medical offers Magnolia Analytics™, a platform that provides hospitals with performance data on blood culture collection processes. This service helps healthcare providers evaluate the clinical and economic impact of their technologies, promoting evidence-based choices. The company holds a robust intellectual property portfolio with over 180 issued patents and more than 50 pending applications, emphasizing their commitment to innovation in diagnostic accuracy and patient safety.

• Employees 89
• Founded 2006
• Annual Revenue $18400000
• Total Funding $117162325